Arash Rezazadeh Kalebasty

12PUBLICATIONS
74CO-AUTHORS
Molecular targetsEpigenetics (incl. genome methylation and epigenomics)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 24, 2026
Comparative Pharmacovigilance Analysis of Safety Signals Among Advanced Prostate Cancer Therapies Using FAERS (FDA Adverse Event Reporting System).

|Aug 07, 2025
Comprehensive Comparison of Somatic, Germline, and Immune Cell Profiles in Upper Tract and Bladder Urothelial Carcinoma.

Kit Yuen, Margaret Meagher, Jacob Mercer

|Jul 29, 2025
Genes Encoding Multiple Modulators of the Immune Response Are Methylated in the Prostate Tumor Microenvironment of African Americans.

Vinay Kumar, Tara Sinta Kartika Jennings, Lucas Ueta

|Oct 16, 2024
The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond.

Farshad Sheybaee Moghaddam, Sami Dwabe, Nataliya Mar

|Aug 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Daniel P Petrylak, Scott T Tagawa, Rohit K Jain

|Aug 01, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer.

Yohann Loriot, Arjun V Balar, Daniel P Petrylak

Pageof 2

Frequent Collaborators

4 joint publications

Petros Grivas

4 joint publications

Cora N Sternberg

3 joint publications

Scott T Tagawa

3 joint publications

Daniel P Petrylak